Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7084245	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 8 months from now)
US7414105	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 8 months from now)
US7919118	TAKEDA PHARMS USA	Spacer moiety for poly (ethylene glycol) modified peptide based compounds	May, 2024 (1 year, 8 months from now)
US7528104	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 8 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550433	TAKEDA PHARMS USA	Erythropoietin receptor peptide formulations and uses	Jun, 2026 (3 years from now)
US7919461	TAKEDA PHARMS USA	Erythropoietin receptor peptide formulations and uses	Jun, 2026 (3 years from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 10MG BASE/ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued